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Background: Improved treatment approaches for ulcerative colitis (UC), including novel medications, might reduce the need for colectomy. 
We performed a retrospective cohort study of adult patients (age 18–64) with UC in the United States to examine time trends for colectomy and 
biologic use from 2007 to 2016.
Methods: We estimated quarterly rates for colectomy and biologic use using the IQVIA Legacy PharMetrics Adjudicated Claims Database. We 
used interrupted time series methods with segmented regression to assess time trends with 95% confidence intervals (CIs) for biologic use and 
colectomy before and after the emergence of newly available biologic therapies in 2014.
Results: Among 93,930 patients with UC, 2275 (2.4%) underwent colectomy from 2007 to 2016. Biologic use rates increased significantly from 
2007 to 2016, from 131 per 1000 person-years in 2007 (95% CI, 121 to 140) to 589 per 1000 person-years in 2016 (95% CI, 575 to 604; P < 0.001). 
Colectomy rates decreased significantly between 2007 and 2016, from 7.8 per 1000 person-years (95% CI, 7.4 to 8.2) to 4.2 per 1000 person-years 
in 2016 (95% CI, 3.2 to 5.1; P < 0.001). An interruption in 2014 was associated with a positive trend deflection for biologic use (+72 treatments 
per 1000 person-years per year (95% CI, 61 to 83) and a negative trend deflection for colectomy (–0.76 per 1000 person-years per year; 95% CI, 
–1.47 to –0.05).
Conclusions: Among commercially insured patients in the United States from 2007 to 2016, biologic use rates increased, colectomy rates de-
creased, and both trends were impacted by the interruption in 2014. These findings suggest that new biologic therapies may have contributed to 
decreased colectomy rates.
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INTRODUCTION
In the past 15 years, the number of medications avail-
able for the treatment of ulcerative colitis (UC) has increased 
significantly. These new therapies act through multiple mech-
anisms, and biologic therapies in particular are being utilized 
earlier in the disease course than in prior eras of treatment for 
UC. If  these new approaches are effective in altering the clin-
ical course of disease, the need for colectomy may decrease or 
be delayed.
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Population-based estimates of the frequency of colec-
tomy among patients with UC have varied considerably over 
time.1 Although early reports of the frequency of colectomy 
ranged as high as 20%–45% in patients up to 25  years after 
diagnosis,1 in other population-based or prospectively enrolled 
cohort studies, the risk of colectomy reported was lower.2–4 
A recent meta-analysis estimated that the 10-year risk of sur-
gery among patients with UC was 15.6%.5 Additionally, the 
indication for colectomy appears to have changed over time, 
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with an increasing proportion of colectomies being performed 
for fulminant colitis or neoplasia compared with medically re-
fractory disease.6
The therapeutic landscape for UC is rapidly evolving, 
with multiple new biologic and small molecule therapies ap-
proved since 2014.7, 8 Recent guidelines for the management of 
UC advocate for an evaluation of disease activity and an assess-
ment of disease prognosis when choosing a therapy,9 perhaps 
leading to earlier treatment with biologic therapy. Infliximab, 
the first biologic therapy to be approved for the treatment of 
UC, has been associated with decreased rates of colectomy in 
retrospective and placebo-controlled studies.10–12 It is unknown 
whether overall colectomy rates in the United States have been 
meaningfully impacted by newer biologic therapies or the 
earlier introduction of biologic therapies into management al-
gorithms for UC.13
The primary objective of this study was to evaluate the 
rates of colectomy for UC over time between 2007 and 2016 
among commercially insured patients in the United States. 
Additionally, we examined trends over time in use of biologic 
therapies among patients with UC and the rate of colectomy 
performed for colorectal cancer.
METHODS
Data Source
For this study of colectomy rates in the UC popula-
tion, we used the IQVIA Legacy PharMetrics Adjudicated 
Claims Database, which contains longitudinal, de-identified, 
individual-level administrative claims for medical, surgical, and 
prescription drug services in the United States from January 
1, 2007, to June 1, 2016. Approximately 100 health plans 
are included in this data source, with a total of 27,800,023 
de-identified individuals represented. In prior published liter-
ature, this data source has been reported as representative of 
the commercially insured population in the United States on a 
variety of measures, including age, sex, geographic region, and 
health plan type.14, 15
Patient Selection
We identified adult patients age 18–64 with UC using pre-
viously described criteria.15, 16 Briefly, we extracted all claims with 
an International Classification of Diseases, 9th revision, Clinical 
Modification (ICD-9-CM) or ICD, 10th revision, Clinical 
Modification (ICD-10-CM) diagnosis code for UC (556.x for 
ICD-9-CM and K51.x for ICD-10-CM) and dispensing/ad-
ministration of inflammatory bowel disease (IBD)–specific 
medications (mesalamine, olsalazine, balsalazide, sulfasala-
zine, azathioprine, mercaptopurine, infliximab, adalimumab, 
certolizumab, golimumab, natalizumab, or vedolizumab). We 
identified claims for these medications by searching their ge-
neric names and anatomical therapeutic chemical codes in the 
National Drug Data File (NDDF Plus; First Databank; www.
firstdatabank.com) to ascertain National Drug Codes for pre-
scription dispensation claims and CPT or Healthcare Common 
Procedure Coding System (HCPCS) codes for biologic proce-
dure claims. To classify as having a diagnosis of UC, patients 
were required to have at least 1 diagnosis code for UC at 3 dis-
tinct health care encounters or at least 1 diagnosis code for UC 
with an accompanying claim for an IBD-specific medication.
Outcome Measures
The primary outcome of interest for this study was the 
rate of colectomy in patients with UC. We identified colec-
tomy based on Current Procedural Terminology (CPT) codes 
for the first observed operation among 3 types of total colec-
tomy procedures: total abdominal colectomy (44150, 44151, 
44210), total proctocolectomy (44155, 44156, 44212), and total 
proctocolectomy with ileal pouch–anal anastomosis (IPAA; 
44157, 44158, 44211). Similar methods of identifying patients 
with UC undergoing colectomy have been utilized in prior 
studies evaluating administrative claims data.17
Second, we measured the rate at which the following bio-
logic medications were used by patients with UC: adalimumab, 
certolizumab, golimumab, infliximab, natalizumab, or 
vedolizumab. We analyzed use of biologic medications among 
the entire population of patients with UC and in separate evalu-
ations of patients who underwent colectomy and those who did 
not undergo colectomy during the study period. In the evalua-
tion of biologic use among colectomy patients, we evaluated bi-
ologic use in the quarter where colectomy occurred. Finally, we 
analyzed the annual and quarterly frequency of colectomy with 
a concomitant diagnosis of colorectal cancer during the study 
period. For the evaluation of colectomy for colorectal cancer 
among patients with UC, we identified patients with a diag-
nosis code of colorectal cancer (ICD-9-CM 153.x-154.8, 230.3, 
230.4; ICD-10-CM C18, C19, C20)18 within the 3 months be-
fore colectomy.
Covariates
Available patient demographics included age, sex, and 
US Census region. We also used the Deyo Modification of the 
Charlson Comorbidity Index to assess comorbidities that po-
tentially influence the likelihood of undergoing colectomy as a 
therapy for UC.19
Statistical Analysis
We estimated rates of biologic use and colectomy on a 
quarterly basis. The denominator for each quarterly rate was 
the accumulated person-years of follow-up with insurance cov-
erage by patients with UC in that quarter. The numerator for 
each quarterly rate was the number of those patients who ex-
perienced the outcome. Follow-up for ascertainment of colec-
tomy and biologic use began at the time of the patient’s first UC 
diagnosis code. Patient follow-up accrued until disenrollment 
from a health plan in the database, loss of prescription drug 
coverage for >1  month, age 65, or June 1, 2016—whichever 
came first. Among patients who underwent colectomy, fol-
low-up for both outcomes was terminated at the time of their 
colectomy. We excluded patients who had <3 months of contin-
uous insurance enrollment after UC diagnosis.
To estimate time trends in rates of biologic use and colec-
tomy and to assess how these may have been impacted by newly 
available biologics, we conducted an interrupted time series 
analysis. This is a common study design to assess changes in 
time trends that take place after well-defined population-level 
changes (eg, new policies or guidelines), when randomization 
is not possible.20, 21 Three new biologic therapies were approved 
for the treatment of UC between 2012 and 2014 (adalimumab, 
golimumab, and vedolizumab). Given that vedolizumab was 
approved by the Food and Drug Administration (FDA) in 
May 2014, we allowed a 6-month lag until the fourth quarter 
of 2014 as the a priori “interruption” that would mark deflec-
tions in trends for biologic use and colectomy. We hypothesized 
that changes in rates of biologic use and colectomy would be 
gradual, and therefore did not model discontinuities between 
segments.22, 23
We used ordinary least squares for segmented linear regres-
sion models to estimate linear trends before and after the 2014 
interruption, with 95% confidence intervals (CIs). We controlled 
for confounding by seasonality using a transformed cosine peri-
odic function.24, 25 To account for autocorrelated error over time, 
we used Durbin-Watson tests (α = 0.05) lagged up to 3 years.26
We performed all data management and analysis using R, 
version 3.5.1 (R Foundation for Statistical Computing, Vienna, 
Austria), and SAS, version 9.4 (SAS Institute, Cary, NC, USA), 
including the AUTOREG and MODEL (with %AR macro) 
procedures to implement segmented regression. The study pro-
tocol was exempted by the Institutional Review Board at the 
University of North Carolina at Chapel Hill.
RESULTS
We identified 93,930 UC patients for this study. Clinical 
and demographic characteristics of the study population are re-
ported in Table 1. Among all patients with UC, 51,393 (55%) 
were women with a median age of 55 years at the time of last 
follow-up [interquartile range (IQR) 44–63 years].  The median 
follow-up time for all patients with UC was 5.5 years (IQR 
3.2–7.0 years).
Among 93,930 patients with UC, 2275 (2.4%) under-
went colectomy during the study period; 1082 patients (48%) 
underwent a total abdominal colectomy, 375 (16%) underwent 
a total proctocolectomy, and 818 (36%) underwent a total 
proctocolectomy with IPAA. The quarterly rate of colectomy 
among UC patients decreased between 2007 and 2016, from a 
peak of 8.4 per 1000 person-years in quarter 4 (Q4)–2007 to a 
minimum of 4.1 per 1000 person-years in Q2-2016 (Fig. 1).
Impact of Newly Available Biologics for 
Ulcerative Colitis
The rates of (A) biologic use and (B) colectomy in pa-
tients with UC are presented in Figure 2, along with seasonality-
adjusted trend estimates from our interrupted time series 
analysis. In patients with UC, the rate of biologic use increased 
over time from 2007 (131 per 1000 person-years; 95% CI, 121 to 
140) until the interruption in 2014 (402 per 1000 person-years;
95% CI, 393 to 411). During this pre-interruption period, the
increasing trend for biologic use rates was 35 per 1000 person-
years per year (95% CI, 33 to 37; P < 0.001). The interruption
in 2014 was associated with a further positive trend deflec-
tion of +72 per 1000 person-years per year (95% CI, 61 to 83;
P < 0.001; null impact of interruption would be 0 deflection).
As a result, the postinterruption trend was 107 per 1000 person-
years per year (95% CI, 97 to 117; P  <  0.001). By 2016, the
biologic use rate had reached 589 per 1000 person-years (95%
CI, 575 to 604).
The colectomy rate in UC patients decreased by 24% 
from 2007 (7.8 per 1000 person-years; 95% CI, 7.4 to 8.2) until 
the interruption in 2014 (5.9 per 1000 person-years; 95% CI, 
5.5 to 6.3). During this pre-interruption period, the decreasing 
trend for colectomy rates was –0.24 per 1000 person-years per 
year (95% CI, –0.33 to –0.15; P < 0.001). The interruption in 
2014 was associated with a further negative trend deflection of 
–0.76 per 1000 person-years per year (95% CI, –1.47 to –0.05;
P = 0.044; null association would be 0 deflection). As a result,
TABLE 1. Demographic and Clinical Characteristics 
of Patients with Ulcerative Colitis in the United States, 
IQVIA Legacy PharMetrics Adjudicated Claims Database, 
2007–2016
Patients With UC 
(n = 93,930)
Median IQR
Age at last follow-up, y 55 (44–63)
Person-years of follow-up 5.5 (3.2–7.0)
No. %











the postinterruption trend was –1.00 per 1000 person-years per 
year (95% CI, –1.66 to –0.35; P = 0.005). By 2016, the colec-
tomy rate had reached its nadir, at 4.2 per 1000 person-years 
(95% CI, 3.2 to 5.1). In a subanalysis of patients with UC 
undergoing colectomy, there was no significant difference in the 
rate of colectomy performed for colorectal cancer during the 
study period (Supplementary Fig. 1).
Figure 3 shows the quarterly proportion of patients 
with UC who used each biologic. From 2007 to 2016, use of 
infliximab increased from 2.9% to 4.9% among patients with 
UC, whereas use of adalimumab increased from 0.3% in 2007 
to 2.6% in 2012 to 6.3% in 2016. After FDA approval of 
vedolizumab in 2014, the proportion of patients with claims for 
vedolizumab reached a maximum of 1.4% of patients with UC 
by 2016. Among patients undergoing colectomy, the percentage 
of patients with a biologic claim in the same quarter increased 
by a mean of 0.23 absolute percentage points per quarter (linear 
trend test, P = 0.024) during the study period, whereas the per-
centage of patients who did not undergo colectomy with a bi-
ologic claim increased by 0.24 absolute percentage points per 
quarter (linear trend test, P < 0.001) during the study period.
DISCUSSION
In this evaluation of health care claims from more than 
90,000 commercially insured patients with UC in the United 
States, we observed a decrease over time in the rate of colec-
tomy between 2007 and 2016. This decrease was demonstrated 
on multiple analyses, including segmented regression of inter-
rupted time series data based on an interruption in 2014 repre-
senting the emergence of newly available biologic medications. 
During the same time period, rates of biologic use significantly 
increased among patients with UC. The decrease in colectomy 
rate during the study period represents one of the first evalu-
ations of colectomy patterns in a commercially insured popula-
tion in the United States during the current biologic era, when 
earlier and more aggressive biologic treatment regimens have 
been advocated.27
Although historically the lifetime risk of colectomy for 
an individual patient has been estimated to be ≥25% for patients 
with UC in population-based cohorts,1, 28 more recent analyses 
have demonstrated a lower risk of colectomy at 10 years after 
diagnosis (~15%).5 Thus far, the impact of early and more ag-
gressive use of biologic therapy on long-term outcomes such as 
colectomy among patients with UC in the United States has not 
been well established. A prior study from Kaplan et al. demon-
strated a decreased rate of elective colectomy among patients 
with UC in Alberta, Canada, from 1997 to 2009, along with 
a significant increase in thiopurine (1997–2009) and infliximab 
use (2005–2009).9 Although a decrease in early colectomy rates 
was noted from 1998 to 2005 in a Dutch population-based co-
hort when compared with previous years, there were no differ-
ences in late colectomy rates between 1991 and 2010.2
In an evaluation from Ontario, Canada, using data from 
1995 to 2012, the marketplace introduction of infliximab was 
not associated with a decrease in colectomy among patients 
with UC,29 whereas a study from Edmonton, Canada, demon-
strated a decrease in colectomy rate after 2005, which paralleled 
the increased use of infliximab.30 In our study of a more recent 
decade (2007–2016), we have evaluated the early biologic era 
after the approval of infliximab for the treatment of UC and 
FIGURE 1. Incidence rates of colectomy per 1000 person-years among patients with ulcerative colitis in the United States, IQVIA Legacy PharMetrics 
Adjudicated Claims Database, 2007–2016. P < 0.001.
the current biologic era, which includes additional anti-TNF 
therapies and a new mechanism of action in the form of anti-
integrin therapy. Additionally, this more modern era of anal-
ysis likely incorporates current practice patterns where earlier 
introduction of biologic therapy into the treatment paradigm 
is favored if  not recommended.27, 31 A recent study from Japan 
demonstrated a similar increase in anti-TNF therapy and 
calcineurin inhibitor use during a similar time period, along 
with a decrease in surgery rates for UC.32
Our segmented regression analyses demonstrated that 
colectomy rates decreased from 2007 until the interruption 
in 2014, with an even more precipitous decrease noted after 
the interruption through the end of the study period in 2016. 
Biologic use rates were also meaningfully impacted by the in-
terruption in 2014, after which the increasing trend in biologic 
use became even steeper. We identified this interruption a priori 
under the hypothesis that 2014 was a period of introduction 
and increased utilization of the newest biologic therapies for 
UC (adalimumab, golimumab, and vedolizumab). Prior studies 
utilizing administrative claims data from the United States 
have also demonstrated a consistent rise in biologic use for 
UC during this same time period.33 Changes in the pattern 
FIGURE 2. Segmented trends over calendar time for quarterly incidence rates of (A) biologic use and (B) colectomy per 1000 person-years among 
patients with ulcerative colitis in the United States, IQVIA Legacy PharMetrics Adjudicated Claims Database, 2007–2016. A, Biologic use: pre-
interruption period, P < 0.001; trend deflection at interruption, P < 0.001; postinterruption period, P < 0.001. B, Colectomy: pre-interruption period, 
P < 0.001; trend deflection at interruption, P = 0.044; postinterruption period, P = 0.005. Pointwise quarterly rates (circles), pre- and postinterruption 
trend segments (solid lines), and projected postinterruption trend based on pre-interruption trend (dashed lines) are shown separately in each 
panel for each outcome.
of colectomies among inpatients in the United States during 
an early portion of this time period have been reported using 
the HCUP Nationwide Inpatient Sample13; however, this data 
source lacks a mechanism to follow patients longitudinally 
and does not include medications. Whether the trends demon-
strated in our study represent a significant shift in the natural 
history of UC or a temporary delay in surgery with a potential 
rebound in colectomy rates in the future is unknown. This ques-
tion will require vigilant follow-up in future iterations of this 
data source and confirmation in other large, population-based 
longitudinal cohorts.
In our evaluation of the rate of colectomy performed for 
colorectal cancer among patients with UC, there was no signif-
icant change from 2007 to 2016. A recent evaluation of colec-
tomy patterns in Helsinki demonstrated a similar decrease in 
colectomy rate during the current biologic era, without a sig-
nificant difference in the percentage of colectomies performed 
for colorectal cancer or dysplasia.34 There have been several 
recent changes in the approach to specific findings on surveil-
lance colonoscopy among patients with UC, including recom-
mendations from the SCENIC consensus statement,35 in which 
surveillance colonoscopy is recommended over colectomy in 
multiple scenarios. Despite the overall decrease in colectomy 
rates for UC, the impact of these recommendations and other 
changes in practice patterns may not be fully captured in ad-
ministrative claims data.
The findings of this study are ecological, and they may be 
influenced by other temporal changes in the clinical treatment 
of UC. They may be influenced by other temporal changes in 
clinical treatment of UC. Increased access to IBD specialist 
care may also improve long-term outcomes among patients 
with UC.36 This is particularly true when recognizing comorbid 
conditions that might also increase the risk of colectomy such 
as cytomegalovirus infection or nontherapy interventions such 
as access to a nutritionist, social worker, psychologist, or other 
resources. In addition to an overall use of biologic therapies, 
changes in how these biologic therapies are utilized may also 
significantly impact outcomes, including an increase in the use 
of combination therapy,37 treat-to-target strategies,38, 39 and po-
tentially therapeutic drug monitoring.40
This study has several strengths. Our interrupted time 
series analysis examined a critical 10-year period in the man-
agement of UC, during which several new medications became 
available. We leveraged reliable administrative claims data to 
analyze a large sample of patients with UC using validated 
case-finding definitions, records of medication dispensing and 
infusion, and colectomies. However, it is recognized that di-
sease extent influences risk of colectomy,41 and we were unable 
to assess for disease extent or severity. Similarly, due to the re-
strictions of administrative claims data, we were only able to 
evaluate those patients with a diagnosis of colorectal cancer be-
fore colectomy. There are also limitations when analyzing bio-
logic use using administrative claims. There may be incomplete 
capture of inpatient biologic utilization, given that bundling 
of inpatient costs may occur. Furthermore, if  patients utilized 
manufacturer assistance programs, biologic use patterns would 
not be completely captured. Both of these measurement lim-
itations would suggest that our estimates of sharp increasing 
trends for biologic use are underestimations, if  they are indeed 
biased. When identifying patients with UC, we recognize that 
some patients will potentially continue to have documented di-
agnosis codes for UC despite having previously undergone co-
lectomy (potentially before enrollment). Although this likely 
represents a small subset of this population, this could inflate 
the total number of patients with UC while not representing 
true eligibility for colectomy. Due to the lack of granularity in 
this regard in the available claims data, we could not overcome 
this limitation for this study.
In conclusion, among a large, geographically diverse 
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FIGURE 3. Trends in percentage of patients with claims for biologic therapies over time, among patients with ulcerative colitis in the IQVIA Legacy 
PharMetrics Adjudicated Claims Database, analyzed by regimen. Other biologics: golimumab, certolizumab, natalizumab.
demonstrated a significant decrease in the rate of colectomy 
from 2007 to 2016, which became more precipitous after the 
interruption in 2014. The use of biologics increased throughout 
the study period, and began to increase more rapidly in 2014. 
Although other nontherapy factors may have contributed to 
the decrease in colectomy rates, these data suggest that more 
widespread use of biologic therapy has reduced the rate of 
colectomy.
SUPPLEMENTARY DATA
Supplementary data are available at Inflammatory Bowel 
Diseases online.
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